7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 
      
    		                                         
      operating activities:
    		                                         
      net income
    		-67,274,000 -92,574,000 -129,666,000 -59,179,000 -85,752,000 -134,584,000 -134,130,000 -233,414,000 -95,642,000 -138,213,000 -116,583,000 -108,326,000 -111,161,000 -94,835,000 -102,998,000 -91,553,000 -88,429,000 -89,385,000 -80,481,000 -32,132,000 -21,776,000 -20,092,000 -18,383,000 -15,641,000 -15,581,000 -16,682,000 -17,885,000 -17,340,000 -23,635,000 -27,732,000 -27,519,000 -24,487,000 -23,969,000 -23,452,000 -24,515,000 -24,238,000 -31,897,000 -34,024,000 -30,650,000 -76,821,000 -42,649,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                         
      change in fair value of related-party convertible note
    		1,169,000 -1,169,000 42,582,000                                       
      non-cash interest expense related to revenue interest liability
    		9,310,000 10,019,000 13,266,000                                       
      stock-based compensation expense
    		8,878,000 9,648,000 9,537,000 9,038,000 7,489,000 9,639,000 8,266,000 12,774,000 14,449,000 11,062,000 10,878,000 9,350,000 10,630,000 10,175,000 10,024,000 10,180,000 13,840,000 17,863,000 15,298,000 667,000 711,000 316,000 445,000 477,000 277,000 522,000 1,351,000 1,407,000 3,968,000 8,934,000 9,073,000 8,884,000 8,714,000 9,381,000 10,018,000 11,266,000 18,669,000 23,382,000 20,535,000 70,554,000 36,103,000 
      change in fair value of warrant liabilities
    		-14,905,000 -3,889,000 448,000 -9,733,000 -31,324,000 19,300,000 1,802,000 79,400,000 -14,265,000 10,019,000 -27,554,000                               
      depreciation and amortization
    		3,951,000 3,880,000 3,829,000 4,138,000 4,455,000 4,406,000 4,555,000 4,564,000 4,585,000 4,682,000 4,681,000 5,226,000 4,500,000 4,444,000 4,090,000 3,595,000 3,687,000 3,984,000 2,972,000 2,283,000 2,380,000 2,267,000 2,217,000 2,209,000 2,202,000 2,206,000 2,395,000 2,787,000 2,776,000 2,369,000 1,623,000 1,569,000 1,461,000 1,374,000 1,162,000 1,839,000 770,000 513,000 485,000 405,000 25,000 
      change in fair value of derivative liabilities
    		-289,000 -1,931,000 -5,578,000 6,607,000 -1,614,000 -21,194,000 2,724,000                                   
      non-cash lease expense related to operating lease right-of-use assets
    		830,000 905,000 925,000 1,615,000 1,415,000 1,380,000 1,346,000 1,326,000 1,553,000 1,636,000 1,597,000 1,652,000 1,475,000 1,487,000 1,318,000 1,384,000 1,231,000 714,000 1,555,000 1,140,000 968,000 648,000 674,000 679,000 659,000                 
      transaction costs allocated to warrant liabilities
    		2,063,000       0 1,026,000 0 984,000                               
      non-cash lease expense related to operating lease right-of-use assets – related parties
    		698,000 678,000 658,000                                       
      non-cash interest items
    		-63,000 -62,000 -62,000 1,337,000 -62,000 -62,000 -63,000 201,000 3,962,000 2,521,000 2,505,000 -2,024,000 6,848,000 3,524,000 3,398,000   2,813,000 3,435,000 37,000 -398,000 93,000 17,000 73,000 110,000 158,000 -95,000 -32,000 232,000 -58,000 149,000 72,000 178,000 217,000 253,000 -300,000 243,000 -221,000 -295,000   
      accretion of discounts on marketable debt securities
    		-978,000 -11,000 -52,000 -24,000 -580,000 -394,000 -491,000                                   
      unrealized losses on equity securities
    		   112,000 505,000                                     
      amortization of related-party notes discounts
    		   5,007,000 6,199,000 5,832,000 5,549,000 7,118,000 11,454,000 12,288,000 11,536,000                               
      other
    		35,000 211,000 242,000 -37,000 52,000 20,000 74,000 52,000 -582,000 12,000 111,000 400,000 -152,000 -823,000 848,000    -125,000                       
      changes in operating assets and liabilities:
    		                                         
      accounts receivable
    		-9,890,000 -5,097,000 -14,669,000 1,815,000 -3,142,000                                   0 -25,000 
      inventories
    		-63,000 1,804,000 -172,000 -6,314,000 -147,000                                     
      prepaid expenses and other current assets
    		-5,578,000 -3,939,000 114,000 1,333,000 -2,778,000 1,514,000 1,634,000 -3,505,000 -1,777,000 1,551,000 9,689,000 -2,137,000 54,000 -14,256,000 -218,000 -2,674,000 -4,995,000 6,354,000 -934,000 963,000 -3,218,000 683,000 244,000     2,634,000 -11,908,000 303,000 -847,000 732,000          
      prepaid expenses – related parties
    		738,000 -205,000 951,000                                       
      other assets
    		-324,000 1,227,000 -84,000 -1,034,000 -255,000 49,000 132,000 528,000 338,000 752,000 295,000  1,439,000 598,000 101,000  -645,000 -4,892,000 693,000 -455,000 -51,000 -168,000 335,000     66,000 -1,229,000   -6,000 12,000 326,000 126,000 78,000 237,000 175,000 -337,000 -33,000 2,431,000 
      accounts payable
    		-1,392,000 -6,216,000 6,439,000 -3,214,000 -8,922,000 4,655,000 4,314,000 -2,877,000 -2,730,000 -1,537,000 668,000 437,000 1,028,000 5,740,000 795,000 -3,547,000 -2,770,000 -3,897,000 6,497,000 -2,111,000 3,078,000 -95,000 1,270,000 -301,000 407,000 -735,000 670,000 -1,034,000 -1,941,000 1,758,000 117,000 -1,343,000 2,560,000 -1,792,000 725,000 567,000 237,000 821,000 -737,000 -3,188,000 1,767,000 
      accrued expenses and other liabilities
    		5,469,000 8,723,000 -12,933,000 -2,114,000 6,226,000 3,297,000 -8,917,000 -19,516,000 -1,659,000 9,274,000 18,590,000 -3,151,000 6,651,000 -10,289,000 10,891,000 4,558,000 4,445,000 -1,928,000 -1,893,000 2,112,000 103,000 474,000 997,000 -398,000 843,000 -13,262,000 797,000 -1,911,000 14,016,000 -1,275,000 1,878,000 147,000 658,000 -1,538,000 434,000 -327,000 816,000 402,000 1,236,000   
      due to and due from related parties
    		501,000 -7,000 51,000                                       
      operating lease liabilities
    		-912,000 -992,000 -916,000 -1,537,000 -1,516,000 -1,522,000 -898,000 -549,000 -1,108,000 190,000 -1,511,000 -2,013,000 -112,000 -1,855,000 -339,000 -517,000 -670,000 -1,503,000 -1,474,000 -1,287,000 -1,118,000 -778,000 -758,000 -737,000                  
      operating lease liabilities – related parties
    		-881,000 -852,000 -816,000                                       
      net cash from operating activities
    		-68,907,000 -79,746,000 -85,905,000 -85,144,000 -98,763,000 -100,347,000 -106,982,000 -115,271,000 -87,403,000 -79,773,000 -84,310,000 -90,727,000 -80,600,000 -91,252,000 -74,930,000 -71,639,000 -72,716,000 -69,595,000 -60,469,000 -23,056,000 -18,280,000 -16,521,000 -12,596,000 -14,885,000 -16,572,000 -16,827,000 -13,078,000 -14,033,000 -17,571,000 -16,266,000 -15,511,000 -13,640,000 -10,133,000 -14,950,000 -10,057,000 -10,753,000 -10,683,000 -8,301,000 -8,856,000 -11,085,000 -4,178,000 
      capex
    		-741,000 -1,081,000 -1,121,000 -2,111,000 -2,792,000 -724,000 -1,261,000 -7,955,000 -5,675,000 -8,526,000 -8,428,000 -18,931,000 -15,935,000 -15,949,000 -27,347,000 -10,403,000 -8,032,000 -8,045,000 -7,083,000 -401,000 -1,698,000 -394,000 -146,000 -680,000 -413,000 -985,000 -2,104,000 -2,045,000 -3,663,000 -2,492,000 -4,902,000 -11,433,000 -10,717,000 -8,156,000 -4,509,000 0 -3,079,000 -1,056,000 -1,067,000 -955,000 -1,134,000 
      free cash flows
    		-69,648,000 -80,827,000 -87,026,000 -87,255,000 -101,555,000 -101,071,000 -108,243,000 -123,226,000 -93,078,000 -88,299,000 -92,738,000 -109,658,000 -96,535,000 -107,201,000 -102,277,000 -82,042,000 -80,748,000 -77,640,000 -67,552,000 -23,457,000 -19,978,000 -16,915,000 -12,742,000 -15,565,000 -16,985,000 -17,812,000 -15,182,000 -16,078,000 -21,234,000 -18,758,000 -20,413,000 -25,073,000 -20,850,000 -23,106,000 -14,566,000 -10,753,000 -13,762,000 -9,357,000 -9,923,000 -12,040,000 -5,312,000 
      investing activities:
    		                                         
      purchases of marketable debt securities, available-for-sale
    		-180,586,000 -15,061,000 -100,000 -6,089,000 0 -85,766,000 -48,363,000 -166,000 -9,956,000 -78,000 -158,000 -19,000 -86,000 -125,000 -34,082,000 -139,001,000 -2,483,000 -175,000 -91,000 -5,991,000 -70,791,000 -4,490,000 -10,300,000 -9,787,000 -10,042,000 -16,516,000 -50,273,000 -12,513,000 -28,754,000             
      proceeds from maturities of marketable debt securities, available-for-sale
    		0 0 5,350,000 18,034,000                                      
      purchases of property, plant and equipment
    		-741,000 -1,081,000 -1,121,000 -2,111,000 -2,792,000 -724,000 -1,261,000 -7,955,000 -5,675,000 -8,526,000 -8,428,000 -18,931,000 -15,935,000 -15,949,000 -27,347,000 -10,403,000 -8,032,000 -8,045,000 -7,083,000 -401,000 -1,698,000 -394,000 -146,000 -680,000 -413,000 -985,000 -2,104,000 -2,045,000 -3,663,000 -2,492,000 -4,902,000 -11,433,000 -10,717,000 -8,156,000 -4,509,000       
      software development costs
    		                                         
      proceeds from sales of marketable debt securities
    		    20,040,000              7,094,000                       
      acquisition of a business, net of transaction costs
    		   0                                      
      cash paid for other investments
    		   0                                      
      net cash from investing activities
    		-181,361,000 -16,142,000 4,129,000 9,834,000 65,032,000 -51,490,000 -35,622,000 2,249,000 -15,631,000 -8,604,000 -8,484,000 -18,894,000 -1,168,000 116,672,000 -69,313,000 -137,802,000 10,582,000 10,489,000 31,845,000 6,568,000 -56,247,000 14,927,000 14,163,000 12,163,000 17,374,000 11,378,000 -19,459,000 15,914,000 16,874,000 21,393,000 2,920,000 19,734,000 6,961,000 56,819,000 16,038,000 -8,464,000 6,855,000 -10,151,000 -101,912,000 -171,979,000 -672,000 
      financing activities:
    		                                         
      proceeds from equity offerings, net of issuance costs
    		                                       263,000 245,213,000 
      net share settlement for rsus vesting
    		-151,000 -322,000 -1,202,000 -803,000 -299,000 -496,000 -3,867,000 -1,562,000 -1,464,000 -60,000 -357,000 -219,000 -10,000 -15,000 -372,000  -960,000 0 -2,624,000                       
      proceeds from exercises of stock options
    		0 0 220,000 0 286,000   1,000 32,000 135,000 126,000 0 0 0 74,000 351,000 678,000 3,311,000 1,121,000 259,000 353,000                     
      principal payments of finance leases
    		-12,000   0 -22,000 -21,000 -21,000 -20,000 -19,000 -19,000 -19,000 -18,000                              
      proceeds from the ripa, net of issuance costs
    		   0 0                                     
      proceeds from exercises of warrants
    		   0 15,617,000 43,548,000 14,116,000                                   
      proceeds from exercise of oberland stock option, net of commissions
    		   0 0                                     
      net cash from financing activities
    		173,519,000 172,810,000 -982,000 106,929,000 15,582,000 148,894,000 10,225,000 200,539,000 237,502,000 43,412,000 76,888,000 109,940,000 123,986,000 -15,000 -298,000 325,953,000 42,656,000 98,337,000 38,497,000 241,000 -483,000 87,340,000 -123,000 -61,000 -40,000 -501,000 39,195,000 -370,000 -115,000 -201,000 -85,000 -3,142,000 -14,947,000 -16,426,000 -468,000 -4,104,000 -2,991,000 -6,575,000 -1,890,000 306,000 243,079,000 
      effect of exchange rate changes on cash and cash equivalents, and restricted cash
    		-56,000 76,000 -10,000 -7,000                                      
      net change in cash and cash equivalents, and restricted cash
    		-76,805,000 76,998,000 -82,768,000 31,612,000                                      
      cash and cash equivalents, and restricted cash, beginning of period
    		0 0 143,912,000                                       
      cash and cash equivalents, and restricted cash, end of period
    		-76,805,000 76,998,000 61,144,000                                       
      proceeds from equity offerings, net of discounts and issuance costs
    		   107,732,000 0   15,920,000 37,463,000 -110,000 47,288,000                               
      unrealized losses (gains) on equity securities
    		  1,000                                       
      payment of revenue interest liability
    		      -3,000                                   
      change in fair value of convertible note
    		       36,952,000 -7,517,000                                 
      non-cash interest expense related to the revenue interest liability
    		   10,289,000 10,504,000 9,207,000 8,004,000                                   
      impairment of intangible assets
    		           0                              
      impairment of fixed assets
    		                                         
      related parties
    		   223,000 484,000 214,000 -158,000 170,000 -67,000 -1,171,000 -61,000 414,000 2,220,000 -2,241,000 -1,618,000 -5,473,000 -7,293,000 -18,000 2,597,000                       
      proceeds from sales of marketable debt and equity securities
    		       270,000 0 0 102,000 56,000 99,000   195,000 -1,000                         
      purchase of intangible assets
    		           0 0 0 -21,229,000                           
      investment in joint venture – an equity method investment
    		           0 0 0 -1,000,000                           
      proceeds from issuance of related-party promissory notes net of issuance costs paid
    		                                         
      proceeds from stock issuance in connection with the ripa, net of transaction costs
    		                                         
      payment for contingent consideration
    		           0    0                          
      cash and cash equivalents, and restricted cash, beginning of year
    		                                         
      cash and cash equivalents, and restricted cash, end of year
    		                                         
      proceeds from issuance of related-party promissory notes, net of issuance costs paid
    		        199,000,000   49,750,000                              
      maturities of marketable debt securities, available-for-sale
    		     35,000,000 13,021,000                                   
      effect of exchange rate changes on cash, cash equivalents, and restricted cash
    		     12,000 -39,000 -27,000 -1,000 -10,000 -254,000 161,000 43,000 255,000 -175,000 65,000 44,000 48,000 -109,000                       
      net change in cash, cash equivalents, and restricted cash
    		     -2,931,000 -132,418,000 87,490,000 134,467,000 -44,975,000 -16,160,000 480,000 42,261,000 25,660,000 -144,716,000 116,577,000 -19,434,000 39,279,000 9,764,000                       
      cash, cash equivalents, and restricted cash, beginning of period
    		     0 265,787,000  0 0 104,965,000  0 0 181,280,000  0 0 35,094,000  0 0 15,687,000                   
      cash, cash equivalents, and restricted cash, end of period
    		     -2,931,000 133,369,000  134,467,000 -44,975,000 88,805,000  42,261,000 25,660,000 36,564,000  -19,434,000 39,279,000 44,858,000  -75,010,000 85,746,000 17,131,000  762,000 -5,950,000 23,658,000 1,511,000 -812,000             
      unrealized (gains) on equity securities
    		      -725,000    -135,000                               
      proceeds from sale of marketable debt securities
    		      981,000                                   
      amortization of premiums, net of discounts, on marketable debt securities
    		                                         
      proceeds from sales of property, plant and equipment
    		               0            392,000              
      maturities of marketable debt securities, available for sale
    		           0 14,754,000 99,089,000 14,345,000 11,407,000 600,000                         
      proceeds from the ripa, net of transaction costs
    		                                         
      sale of assets to an entity under common control
    		               0                          
      cash, cash equivalents, and restricted cash, beginning of year
    		                                         
      cash, cash equivalents, and restricted cash, end of year
    		                                         
      amortization of net premiums, net of discounts, on marketable debt securities
    		                                         
      issuance of common stock under “at-the-market” offering, net of offering costs
    		        2,490,000                                 
      proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid
    		          29,850,000                               
      change in fair value of warrant liability
    		                                         
      transaction costs allocated to warrant liability
    		                                         
      unrealized loss on non-marketable equity investment
    		                                         
      deferred tax
    		                                         
      investment and other assets
    		                                         
      amortization of net premiums and discounts on marketable debt securities
    		            10,000    13,000 23,000 225,000 369,000 334,000 46,000 45,000                   
      unrealized (gains) losses on equity securities
    		                  -8,834,000                       
      proceeds from equity offering, net of issuance costs paid
    		               27,582,000 41,922,000    -514,000                     
      loss on equity method investment
    		             3,900,000 197,000                           
      unrealized gains on equity securities
    		              -1,419,000  6,008,000                         
      payment to precision biologics to facilitate deconsolidation
    		                                         
      purchase of non-marketable equity investment
    		                                         
      net share settlement for rsus vesting and warrant exercise
    		                                         
      repurchase of common stock
    		                        0          -1,050,000 -3,949,000 -2,574,000 -6,774,000 -2,550,000  0 
      non-cash interest expense
    		                                         
      realized gains on sales of equity securities
    		                0                         
      change in fair value of contingent consideration
    		                                         
      proceeds from issuance of related-party promissory notes
    		                0 0 40,000,000                       
      change in fair value of contingent consideration obligations
    		                                         
      maturities of marketable debt securities
    		                  31,925,000 11,270,000                      
      unrealized loss on equity investment
    		                                         
      losses (gains) on sales of marketable debt securities
    		                                         
      loss on disposal of assets
    		                           75,000 44,000 54,000 36,000 0    0 0 3,000 15,000   
      loss on impairment of assets
    		                                         
      deferred income tax benefit
    		                           -122,000 -128,000 -124,000 -124,000 -182,000 -98,000 -124,000 -93,000 -152,000 -50,000 -228,000 -145,000   
      due to related parties
    		                   3,943,000 705,000 86,000 300,000 -254,000 -157,000 -520,000 -162,000 -503,000 326,000 -528,000 20,000 803,000 -670,000 115,000 1,314,000 -123,000 126,000 53,000 322,000 742,000  
      deferred rent
    		                                    619,000 531,000 500,000 508,000  
      purchases of debt securities, held-to-maturity
    		                           0              
      purchases of investments in equity securities
    		                                         
      sales of marketable debt securities
    		                   1,690,000                      
      proceeds from equity offering, net of issuance cost paid
    		                                         
      principal payments of financing obligations
    		                              -65,000           
      repurchases of common stock with commissions
    		                                         
      net share settlement for restricted stock unit vesting and warrant and option exercises
    		                                         
      net decrease in cash, cash equivalents, and restricted cash
    		                                         
      cash, cash equivalents and restricted cash, beginning of period
    		                       0 0 0 17,000,000 0 0 0 24,051,000           
      cash, cash equivalents and restricted cash, end of period
    		                              11,375,000           
      loss on sales of marketable debt securities
    		                      1,000                   
      loss on impairment of fixed assets
    		                                         
      purchase of viracta common stock
    		                        0                 
      net share settlement for restricted stock unit vesting
    		                                         
      net increase in cash, cash equivalents, and restricted cash
    		                    -75,010,000 85,746,000 1,444,000 -2,783,000 762,000 -5,950,000 6,658,000 1,511,000 -812,000             
      operating lease right-of-use assets
    		                       0 -553,000 0 -247,000               
      sales/maturities of marketable debt securities
    		                     19,811,000 24,609,000 22,630,000 27,829,000 28,882,000 32,918,000 30,080,000 49,633,000 45,711,000 39,860,000           
      net share settlement for restricted stock unit vesting and option exercises
    		                     -40,000 -123,000                   
      proceeds from exercises of stock options and warrants
    		                                         
      gains on sales of marketable debt securities
    		                                         
      deferred rent and revenue
    		                           -138,000 -131,000 -121,000 -118,000 -121,000 -105,000 1,467,000 -40,000       
      principal payments of financing/capital lease obligations
    		                           -142,000 -137,000   -64,000 -14,948,000         
      loss on impairment and loss on disposal of assets
    		                        0                 
      prepaid expenses, other current assets and other assets
    		                        -4,642,000 10,769,000 88,000               
      purchase of debt securities, held-to-maturity
    		                                         
      principal payments of financing lease obligations
    		                                         
      proceeds from exercise of stock options and warrants
    		                        0 0 39,221,000 0 22,000 12,000 23,000  1,000 37,000 1,154,000    660,000   
      net share settlement for rsu vesting, and option and warrant exercises
    		                        -40,000                 
      reconciliation of cash, cash equivalents, and restricted cash at end of period:
    		                                         
      cash and cash equivalents
    		                        1,012,000 -5,000,000 22,279,000 1,511,000 -812,000 4,926,000 11,196,000           
      restricted cash
    		                        -250,000 -950,000 1,379,000               
      supplemental disclosure of cash flow information:
    		                                         
      cash paid during the period for:
    		                                         
      interest
    		                        5,000 0 3,000 258,000 38,000 145,000 34,000 36,000 394,000 201,000 37,000 37,000      
      income taxes
    		                        0   0 0   0 0   1,000 0 0 1,000 -5,000 5,000 
      supplemental disclosure of non-cash investing and financing activities:
    		                                         
      property and equipment purchases included in accounts payable, accrued expenses, and other liabilities
    		                        -1,120,000 -723,000 2,031,000 227,000 -2,267,000             
      conversion of viracta convertible notes and accrued interest into investment in equity securities of viracta
    		                        0 0 751,000               
      unrealized gains on marketable debt securities
    		                        31,000 122,000 118,000 90,000              
      cashless exercise of stock options and warrants
    		                        0       0    0 0     
      amortization of net premiums on marketable debt securities
    		                         -40,000 41,000 81,000 39,000 142,000 201,000           
      operating lease liability, less current portion
    		                         -754,000 -655,000               
      amortization of operating lease right-of-use assets
    		                          624,000               
      net share settlement for rsu vesting and option exercises
    		                          -26,000  0 -80,000 -43,000 -330,000 0 -159,000 -550,000       
      cashless exercise of stock options
    		                          29,000               
      gain on sales of marketable debt securities
    		                                         
      purchase of investment in equity securities
    		                                         
      repurchase of common stock with commissions
    		                                0         
      restricted cash included in other assets
    		                           0 0 0 179,000           
      property and equipment purchases acquired under capital lease
    		                               0 0         
      estimated fair value of building under build-to-suit lease
    		                                         
      lease incentive with a related party
    		                                         
      purchase of equity investment
    		                                         
      cashless exercise of warrants
    		                            93,000           -230,000 807,000 
      cash, cash equivalents, and restricted cash at end of period
    		                                         
      property and equipment purchases acquired under capital lease expenses
    		                                         
      unrealized gain on marketable debt securities
    		                             107,000 -174,000           
      purchases of marketable debt securities
    		                              -32,038,000           
      net increase in cash, cash equivalents and restricted cash
    		                              -12,676,000           
      reconciliation of cash, cash equivalents and restricted cash at end of period:
    		                                         
      cash, cash equivalents and restricted cash at end of period
    		                              11,375,000           
      property and equipment purchases included in accounts payable and accrued expenses
    		                              5,930,000  4,159,000 10,910,000 2,492,000  -967,000 985,000 1,074,000   
      amortization of net premiums on marketable securities
    		                               299,000 358,000 368,000 572,000 615,000 624,000 517,000 426,000   
      gain on sales of marketable securities
    		                               -7,000 -26,000   -19,000 -49,000 -23,000 -46,000   
      change in value of warrant liability
    		                                         
      loss incurred by inex bio
    		                                       -1,000 0 
      gain on settlement of note payable
    		                                       0 0 
      purchase of cost method investment
    		                               0 0 0 -8,500,000       
      purchases of marketable securities
    		                               -36,240,000 -28,597,000 -21,311,000 -25,207,000 -65,108,000 -42,054,000 -54,440,000 -111,397,000   
      sales/maturities of marketable securities
    		                               67,407,000 46,275,000 86,286,000 54,254,000 58,002,000 51,988,000     
      purchase of inex bio inc., net of cash acquired
    		                                        0 
      proceeds from exercise of stock options
    		                                       35,000 75,000 
      proceeds from exercise of warrants
    		                                       8,000 206,000 
      repayments of notes payable
    		                                         
      net increase in cash and cash equivalents
    		                               2,952,000 -18,119,000 25,443,000 5,513,000 -23,321,000     238,179,000 
      cash and cash equivalents, beginning of period
    		                               0 0 0 8,083,000 0 0 0 175,908,000  0 
      cash and cash equivalents, end of period
    		                               2,952,000 -18,119,000 25,443,000 13,596,000 -23,321,000 -6,819,000 -25,027,000 63,250,000  238,179,000 
      unrealized loss on marketable securities
    		                                         
      estimated fair value of buildings under build-to-suit leases
    		                                   0      
      issuance of warrants in inex bio, inc. acquisition
    		                                        0 
      unrealized gain on marketable securities
    		                                34,000 4,000 70,000 -608,000 -456,000 166,000 796,000   
      lease incentive
    		                                         
      receivables, net, prepaid expenses and other current assets
    		                                         
      prepaid and other current assets
    		                                  -13,000  -1,025,000 -195,000 -160,000   
      principal payments of financing obligation
    		                                  -22,000       
      amortization of finance issuance costs
    		                                         
      amortization of debt discount
    		                                         
      forgiveness of note receivable from related party
    		                                         
      bad debt expense
    		                                         
      accounts receivable, prepaid and other current assets
    		                                         
      proceeds from exercise of class b common stock
    		                                         
      conversion of debt and payables into common stock
    		                                         
      conversion of debt into series c preferred stock
    		                                         
      change in par value from 0.001 to 0.0001
    		                                         
      conversion of accounts payable against note receivable related party
    		                                         
      property, plant and equipment purchases included in accounts payable and accrued expenses
    		                                         
      deferred revenue
    		                                    -6,000 -4,000 -5,000 -7,000 -6,000 
      purchases of property and equipment
    		                                    -3,079,000 -1,056,000 -1,067,000 -955,000 -1,134,000 
      proceeds from debt and equity offerings, net of issuance costs
    		                                         
      repayments of financing obligations
    		                                         
      employee payroll taxes paid related to net share settlement of restricted stock units
    		                                       0  
      effect of exchange rate changes on cash and cash equivalents
    		                                         
      lease incentives
    		                                         
      investment in intangible assets
    		                                        462,000 
      payments on notes payable
    		                                       0 0 
      net decrease in cash and cash equivalents
    		                                     -25,027,000 -112,658,000   
      sales of marketable securities
    		                                      10,552,000   
      operating activities
    		                                         
      amortization of premiums on marketable securities
    		                                         
      notes receivable from related party
    		                                         
      other current assets
    		                                         
      investing activities
    		                                         
      purchase of inex bio, inc., net of cash acquired
    		                                         
      financing activities
    		                                         
      repurchase of stock
    		                                         
      net increase in cash
    		                                         
      cash and cash equivalents, beginning of year
    		                                         
      cash and cash equivalents, end of year
    		                                         
      supplemental disclosure of cash flow information
    		                                         
      issuance of warrants in inex bio acquisition
    		                                         
      notes received for purchase of class b common stock
    		                                         
      estimated fair market value of building under build-to-suit lease
    		                                         
      cash flows used in operating activities:
    		                                         
      change in fair value of warrant derivative liability
    		                                        0 
      change in value of note payable
    		                                         
      changes in operating assets and liabilities, net of effects of acquisition:
    		                                         
      accrued expenses
    		                                        -1,492,000 
      cash flows used in investing activities:
    		                                         
      cash flows from financing activities:
    		                                         
      conversion of debt into preferred series c stock
    		                                         
      finance issuance costs
    		                                         
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.